Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Brief Summary: This partially randomized phase III trial studies isotretinoin with dinutuximab, aldesleukin, and sargramostim to see how well it works compared to isotretinoin alone following stem cell transplant in treating patients with neuroblastoma. Drugs used in chemotherapy, such as isotretinoin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as dinutuximab, may block tumor growth in different ways by targeting certain cells. Aldesleukin and sargramostim may stimulate a person's white blood cells to kill cancer cells. It is not yet known if chemotherapy is more effective with or without dinutuximab, aldesleukin, and sargramostim following stem cell transplant in treating neuroblastoma.


Options:
A: Arm Label: Arm I (isotretinoin) (closed to accrual as of 4/16/2009); Type: ACTIVE_COMPARATOR; Interventions: Drug: Isotretinoin, Other: Laboratory Biomarker Analysis, Other: Pharmacological Study, Other: Quality-of-Life Assessment | Arm Label: Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin); Type: EXPERIMENTAL; Interventions: Biological: Aldesleukin, Biological: Dinutuximab, Drug: Isotretinoin, Other: Laboratory Biomarker Analysis, Other: Pharmacological Study, Other: Quality-of-Life Assessment, Biological: Sargramostim | Intervention Type: BIOLOGICAL; Name: Aldesleukin; Assigned to Arm(s): Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin) | Intervention Type: BIOLOGICAL; Name: Dinutuximab; Assigned to Arm(s): Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin) | Intervention Type: DRUG; Name: Isotretinoin; Assigned to Arm(s): Arm I (isotretinoin) (closed to accrual as of 4/16/2009), Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (isotretinoin) (closed to accrual as of 4/16/2009), Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin) | Intervention Type: OTHER; Name: Pharmacological Study; Assigned to Arm(s): Arm I (isotretinoin) (closed to accrual as of 4/16/2009), Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (isotretinoin) (closed to accrual as of 4/16/2009), Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin) | Intervention Type: BIOLOGICAL; Name: Sargramostim; Assigned to Arm(s): Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin)
B: Intervention Type: BIOLOGICAL; Name: filgrastim; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: dacarbazine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: ifosfamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: melphalan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tretinoin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vindesine; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: autologous bone marrow transplantation; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: peripheral blood stem cell transplantation; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A
C: Arm Label: Arm I (unpurged PBSC collection); Type: EXPERIMENTAL; Interventions: Biological: filgrastim, Drug: carboplatin, Drug: cisplatin, Drug: cyclophosphamide, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: isotretinoin, Drug: melphalan, Drug: topotecan hydrochloride, Drug: vincristine sulfate, Procedure: autologous bone marrow transplantation, Procedure: bone marrow ablation with stem cell support, Procedure: conventional surgery, Procedure: peripheral blood stem cell transplantation, Radiation: radiation therapy | Arm Label: Arm II (unpurged PBSC collection); Type: EXPERIMENTAL; Interventions: Drug: carboplatin, Drug: cisplatin, Drug: cyclophosphamide, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: isotretinoin, Drug: melphalan, Drug: topotecan hydrochloride, Drug: vincristine sulfate, Procedure: autologous bone marrow transplantation, Procedure: bone marrow ablation with stem cell support, Procedure: conventional surgery, Procedure: peripheral blood stem cell transplantation, Radiation: radiation therapy | Intervention Type: BIOLOGICAL; Name: filgrastim; Assigned to Arm(s): Arm I (unpurged PBSC collection) | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: isotretinoin; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: melphalan; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: topotecan hydrochloride; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: PROCEDURE; Name: autologous bone marrow transplantation; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: PROCEDURE; Name: bone marrow ablation with stem cell support; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: PROCEDURE; Name: peripheral blood stem cell transplantation; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection) | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Arm I (unpurged PBSC collection), Arm II (unpurged PBSC collection)
D: Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A

Answer: A